We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+19.43%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$676M
AUM Growth
-$147M
Cap. Flow
-$211M
Cap. Flow %
-31.23%
Top 10 Hldgs %
56.25%
Holding
63
New
9
Increased
11
Reduced
18
Closed
18

Top Buys

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$17M
2
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$6.02M
3
ZBH icon
Zimmer Biomet
ZBH
+$5.83M
4
RGLS
Regulus Therapeutics
RGLS
+$4.5M
5
BAX icon
Baxter International
BAX
+$4.03M

Top Sells

Rank Stock Value
1
TVTX icon
Travere Therapeutics
TVTX
+$25.2M
2
HRTX icon
Heron Therapeutics
HRTX
+$15.1M
3
RXDX
Ignyta, Inc.
RXDX
+$14.9M
4
AERI
Aerie Pharmaceuticals
AERI
+$13.4M
5
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$12.2M

Sector Composition

Rank Sector Weight
1 Healthcare 87.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HRTX icon
1
Heron Therapeutics
HRTX
$90.9M
$55.8M 8.26%
3,455,710
-962,649
-22% -$15.1M
CORI
2
DELISTED
Corium International, Inc.
CORI
$49.2M 7.27%
4,436,726
– –
TVTX icon
3
Travere Therapeutics
TVTX
$5.16B
$42.7M 6.32%
1,716,958
-1,145,220
-40% -$25.2M
HZNP
4
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$39.3M 5.81%
3,097,964
-962,883
-24% -$12.2M
AVDL
5
DELISTED
Avadel Pharmaceuticals
AVDL
$37.5M 5.54%
3,568,122
-565,342
-14% -$5.4M
LJPC
6
DELISTED
La Jolla Pharmaceutical Company
LJPC
$36.8M 5.44%
1,058,138
-199,749
-16% -$6.42M
PETX
7
DELISTED
Aratana Therapeutics, Inc.
PETX
$31.8M 4.7%
5,184,942
– –
ANGO icon
8
AngioDynamics
ANGO
$567M
$30.3M 4.48%
1,770,940
+87,688
+5% +$1.47M
MRTX
9
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$29.1M 4.31%
2,490,801
– –
SCTL
10
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$27.8M 4.12%
3,456,596
– –
ENDP
11
DELISTED
Endo International plc
ENDP
$25.8M 3.82%
3,011,323
+1,764,400
+142% +$17M
ZBH icon
12
CALL
Zimmer Biomet
ZBH
$17.4B
$23.4M 3.46%
+206,000
New +$23.8M
SBBP
13
DELISTED
Strongbridge Biopharma plc.
SBBP
$19.9M 2.95%
2,886,795
+14,867
+0.5% +$103K
IOVA icon
14
Iovance Biotherapeutics
IOVA
$2.24B
$19.3M 2.85%
2,487,622
+211,263
+9% +$1.34M
RXDX
15
DELISTED
Ignyta, Inc.
RXDX
$18.5M 2.73%
1,494,402
-1,446,845
-49% -$14.9M
CPRX
16
DELISTED
Catalyst Pharmaceutical
CPRX
$17.4M 2.57%
6,892,500
-457,500
-6% -$1.25M
NVLN
17
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$13.7M 2.03%
1,948,554
– –
BDSI
18
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$13M 1.92%
4,410,866
-711,228
-14% -$2.17M
ATRS
19
DELISTED
Antares Pharma, Inc.
ATRS
$10.4M 1.54%
3,205,900
-1,597,628
-33% -$4.93M
PRTK
20
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$10.2M 1.51%
406,207
+129,187
+47% +$3.01M
TLGT
21
DELISTED
Teligent, Inc
TLGT
$9.56M 1.41%
142,542
-4,203
-3% -$308K
VCYT icon
22
Veracyte
VCYT
$4.57B
$8.95M 1.32%
1,020,832
-426,034
-29% -$3.46M
ALNY icon
23
Alnylam Pharmaceuticals
ALNY
$36.4B
$8.72M 1.29%
74,208
-106,992
-59% -$9.13M
NTUS
24
DELISTED
Natus Medical Inc
NTUS
$7.67M 1.13%
204,400
+92,900
+83% +$3.28M
AERI
25
CALL
DELISTED
Aerie Pharmaceuticals
AERI
$7.29M 1.08%
+150,000
New +$8.18M
1
2 3

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q3 2017 Portfolio in Review

As of Q3 2017, Broadfin Capital held 63 positions worth $676M, down 18% from $823M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Broadfin Capital withdrew a net $211M in Q3 2017, closing 18 positions and reducing 18 holdings. Its most notable exit was Novadaq Technologies Inc., an estimated $11.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 88% of assets, up from 75% a quarter earlier.

Against the trend, Broadfin Capital opened a new position in Tetraphase Pharmaceuticals, Inc. worth $6.16M.

  • Broadfin Capital's largest Q3 2017 buy was Tetraphase Pharmaceuticals, Inc.: 45,000 shares worth $6.16M.
  • Broadfin Capital added most to Endo International plc in Q3 2017, an estimated $17M increase.
  • Broadfin Capital's biggest Q3 2017 reduction was Travere Therapeutics, cutting an estimated $25.2M.
  • Broadfin Capital fully exited Novadaq Technologies Inc. in Q3 2017, selling an estimated $11.7M.
  • Broadfin Capital's ten largest holdings make up 56% of its $676M portfolio in Q3 2017.
  • Broadfin Capital opened 9 new positions and closed 18 in Q3 2017.
  • Broadfin Capital's portfolio value fell 18% quarter-over-quarter to $676M.

Based on Broadfin Capital's 13F filing for Q3 2017, filed 14 Nov 2017.